MARKET WIRE NEWS

Subscribe to Our Newsletter

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

MWN-AI** Summary

X4 Pharmaceuticals (Nasdaq: XFOR), a Boston-based company dedicated to advancing treatments for rare hematology diseases, has announced a virtual Investor Day set for October 29, 2026. This event, running from 10:00 a.m. to 12:00 p.m. ET, will feature presentations from company management and key opinion leaders focused on mavorixafor, a promising candidate for chronic neutropenia treatment.

The Investor Day will review the progress of X4's pivotal Phase 3 clinical trial, known as the 4WARD trial, and discuss an upcoming Phase 2 study of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF). This Phase 2 trial aims to evaluate patients' ability to reduce their G-CSF dosage while maintaining normal neutrophil counts, a crucial consideration for treatment efficacy and patient quality of life.

Dr. Adam Craig, Executive Chairman of X4 Pharmaceuticals, will lead a discussion with notable hematology experts Dr. Shreyans Gandhi and Dr. Julia Warren, followed by an interactive Q&A session. Dr. Gandhi, a Consultant Haematologist at King’s College Hospital in London, specializes in bone marrow failure and enjoys an extensive academic background with contributions to numerous clinical trials. Dr. Warren, from the University of Pennsylvania and Children's Hospital of Philadelphia, focuses on mitochondrial function in granulocyte development and has significant research interests in congenital neutropenia.

X4 Pharmaceuticals is leveraging its expertise in immune system disorders and CXCR4 biology through the development of mavorixafor, which has already been designated as an oral treatment for WHIM syndrome. Furthermore, mavorixafor has received Fast Track designation from the U.S. FDA for treating chronic neutropenia, presenting a significant commercial opportunity. For registration and additional information, visit the company's website.

MWN-AI** Analysis

X4 Pharmaceuticals (Nasdaq: XFOR) is poised for significant developments, particularly surrounding its upcoming virtual Investor Day on October 29, 2026. This event will highlight the progress of its promising compound, mavorixafor, in the treatment of chronic neutropenia. Investors should closely monitor this event, as it may provide critical insights into the status of the ongoing Phase 3 4WARD clinical trial and the strategic plans for a contemplated Phase 2 trial involving mavorixafor and granulocyte colony-stimulating factor (G-CSF).

The involvement of notable hematologists like Dr. Shreyans Gandhi and Dr. Julia Warren adds credibility and may shed light on the clinical and commercial potential of mavorixafor. Both experts bring extensive experience in bone marrow failure and chronic neutropenia, which could enhance the understanding of mavorixafor's therapeutic efficacy during the fireside chat segment. Their input may also help investors gauge the compound's competitive edge in a market characterized by unmet medical needs.

Given mavorixafor's Fast Track designation from the FDA, there is an optimistic avenue for regulatory pathways and potential market entry, positioning X4 well within a niche yet vital segment of hematology. The commercial opportunity for mavorixafor, especially in the context of chronic neutropenia, could translate into a robust revenue stream if clinical outcomes are favorable.

However, investors are advised to remain cautious. The pathway from clinical trials to market is fraught with uncertainties, as highlighted in X4’s forward-looking statements. Potential risks include trial enrollment, regulatory feedback, and the capacity for capital acquisition. Monitoring the outcomes of this Investor Day could influence stock performance and serve as a barometer for X4's future prospects. Engaging with the insights shared during this session will be key for informed investment decisions.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.

The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of the Phase 3 4WARD clinical trial and will outline a planned Phase 2 clinical trial of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF), designed to assess patients' ability to titrate down their G-CSF dose while maintaining normal neutrophil counts.

The Company will also present the potential commercial opportunity for mavorixafor in chronic neutropenia. Following management’s presentation, Dr. Adam Craig, X4 Pharmaceuticals’ Executive Chairman, will host a fireside chat with leading hematology experts, Dr. Shreyans Gandhi and Dr. Julia Warren, followed by a Q&A session.

Webcast Registration:

Registration for the event is available on the Events and Presentations page of the X4 Pharmaceuticals website. An archived replay will also be available on the X4 Pharmaceuticals website following the event.

X4 Pharmaceuticals Investor Day Guest Speakers

Shreyans Gandhi, MBBS, MD, DNB (Internal Medicine), MRCP, FRCPath, M.Phil
King’s College Hospital NHS Foundation Trust (London)

Dr. Gandhi is a Consultant Haematologist at King’s College Hospital in London, working in the field of myeloid disorders, with a primary interest in bone marrow failure (BMF)/cytopenic disorders and paroxysmal nocturnal hemoglobinuria (PNH), including cellular therapies and stem cell transplantation. He is actively involved in academia, being a college tutor for medical students, trainer/supervisor for junior haematology trainees and examiner at the Royal College of Pathologists, and he has authored more than 100 articles in peer-reviewed journals, and chapters for national textbooks. He is an Associate Editor on the board of Frontiers in Oncology and has reviewer and editorial responsibilities in leading medical and haematological journals. He has served as Chair of the South London Cancer Alliance in Haemato-Oncology, including updating of treatment guidelines.

Dr. Gandhi completed his medical degree (MBBS) and thereafter a residency programme in Internal Medicine (MD and Diplomate of National Board) at King Edward Memorial (KEM) Hospital, University of Mumbai with a first-class MD. He is a member of the Royal College of Physicians and gained his fellowship in haematology and specialist training in bone marrow failure disorders at King’s College Hospital in London. He is actively involved in the academic and research activities at the BMF unit at King’s College Hospital.

Dr. Gandhi pursues research on telomere genetic disorders and its multi-system manifestation in BMF. His bench work on RTEL1 was published in Blood Advances. He has been an investigator on numerous Phase 1-3 clinical trials, including cellular therapies and on novel anti-complement drugs. His current academic and research work involve the development and application of ex-vivo expanded T regulatory cells in aplastic anaemia and other auto-immune disorders, the genetic characterization and algorithms in the diagnosis and manifestation of BMF disorders, and the development of a novel assay to assess telomerase activity. Dr. Gandhi has lectured extensively on BMF and PNH and enjoys being a patient advocate at various patient support group societies (aplastic anaemia/PNH and myelodysplastic syndromes and has also represented the rare disease groups (BMF) at the Health Select Committee of the United Kingdom Parliament.

Julia Warren, MD, PhD
Children's Hospital of Philadelphia and University of Pennsylvania

Dr. Warren is a pediatric hematologist and physician-scientist at the University of Pennsylvania and Children's Hospital of Philadelphia (CHOP), and an Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine). Her laboratory program at CHOP/Penn Medicine is focused on understanding mitochondrial function in early granulocyte fate decisions, as well as pre-malignant clonal evolution in congenital neutropenia. Her long-term goals are to understand determinants of normal granulopoiesis that will support the production of off-the-shelf granulocyte transfusion products, and to better identify and treat pre-malignant myeloid clones in bone marrow failure syndromes. Dr. Warren’s research has been supported by the National Heart, Lung, and Blood Institute (NHLBI) and the American Society of Hematology (ASH), among others. Her research interests continue to be informed by her patients, whom she sees through CHOP’s Comprehensive Bone Marrow Failure Center and Cancer Predisposition Clinic programs, with a specialized interest in patients with chronic neutropenia disorders.

Dr. Warren completed her MD and PhD (Immunology) training at Washington University in St. Louis, followed by pediatric residency and hematology/oncology fellowship training as a member of the Oliver Langenberg Physician-Scientist Training Program at Washington University in St. Louis. Her fellowship research focused on normal and malignant myeloid biology and included the identification of novel germline genetic variants impacting mitochondrial function as a cause of congenital neutropenia. Her work also provided evidence for mitochondrial dysfunction in impaired granulocyte precursor survival/differentiation.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the status of the Phase 3 4WARD clinical trial; the design, objectives and initiation of a planned Phase 2 clinical trial of mavorixafor in combination with G-CSF; the potential of mavorixafor as a treatment for chronic neutropenia; and the potential commercial opportunity for mavorixafor in chronic neutropenia. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks related to the initiation, enrollment, conduct, timing and results of clinical trials; feedback from regulatory authorities; the limitations of market research; X4’s ability to obtain sufficient capital; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s most recent Annual Report on Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.


FAQ**

How does X4 Pharmaceuticals Inc. (XFOR) plan to leverage the data from the Phase 3 4WARD clinical trial to enhance investor confidence during the upcoming virtual Investor Day on October 29, 2026?
X4 Pharmaceuticals Inc. plans to leverage the Phase 3 4WARD trial data by highlighting key efficacy and safety outcomes to demonstrate strong clinical potential, thereby bolstering investor confidence during the virtual Investor Day on October 29, 2026.
What specific potential commercial opportunities for mavorixafor in chronic neutropenia will X4 Pharmaceuticals Inc. (XFOR) highlight during the presentations at the Investor Day?
X4 Pharmaceuticals Inc. (XFOR) is likely to highlight mavorixafor's potential to address unmet needs in chronic neutropenia treatment, including its efficacy, safety profile, and ability to improve patients' quality of life in their upcoming Investor Day presentations.
Can X4 Pharmaceuticals Inc. (XFOR) elaborate on the design and anticipated outcomes of the planned Phase 2 clinical trial of mavorixafor in combination with G-CSF?
X4 Pharmaceuticals is expected to provide details on the Phase 2 trial design and anticipated outcomes for mavorixafor in combination with G-CSF, focusing on its efficacy and safety in treating specific conditions, along with potential market implications.
How do the insights from experts like Dr. Shreyans Gandhi and Dr. Julia Warren during the Investor Day contribute to the understanding of mavorixafor's potential effectiveness in chronic neutropenia for X4 Pharmaceuticals Inc. (XFOR)?
Insights from experts Dr. Shreyans Gandhi and Dr. Julia Warren during Investor Day enhance understanding of mavorixafor's potential effectiveness in chronic neutropenia by providing data on its mechanism and clinical outcomes, thus bolstering investor confidence in X4 Pharmaceuticals Inc.'s prospects.

**MWN-AI FAQ is based on asking OpenAI questions about X4 Pharmaceuticals Inc. (NASDAQ: XFOR).

X4 Pharmaceuticals Inc.

NASDAQ: XFOR

XFOR Trading

-0.96% G/L:

$3.085 Last:

341,066 Volume:

$3.20 Open:

iqst Ad 300

XFOR Latest News

$322,204,195
76,629,513
N/A
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston

Check Your Online Brokerage For XFOR

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News